Scholarlink

Purpose <p>The purpose of this study was to comprehensively assess the efficacy of lymph node ratio (LNR) and log odds of positive lymph nodes (LODDS) in predicting survival outcomes in non-elderly locally advanced rectal cancer (LARC) patients treated with neoadjuvant chemoradiotherapy (NCRT).</p> Methods <p>The 1643 non-elderly LARC patients undergoing NCRT between 2010 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database and were randomly assigned at a ratio of 7:3. We used Cox regression models to identify independent prognostic factors, then constructed nomogram models to predict cancer-specific survival (CSS) and overall survival (OS). The relative weight in nomogram models, receiver operating characteristic (ROC), area under the curve (AUC), concordance index (C-index), calibration curve, and decision curve analysis (DCA) were performed to evaluate and compare the predictive performance between LNR and LODDS.</p> Results <p>The distribution of LNR and LODDS showed that LODDS exhibited a more detailed stratification when LNR was equal to the extreme value. In predicting CSS, the LNR (hazard ratio (HR), 1.987; 95% confidence interval (CI), 1.375–2.872) and LODDS (HR, 1.568; 95% CI, 1.154–2.131) were independent risk factors in corresponding nomogram models. Regarding OS, the LODDS (HR, 1.387; 95% CI, 1.060–1.816) showed an independent predictive value. All evaluation methods confirmed the reliability of both models. Although the LNR-based model showed better performance for short-term CSS and the LODDS-based model demonstrated slightly better prediction for long-term CSS and OS, these two models showed largely comparable predictive ability.</p> Conclusions <p>The LNR and LODDS can provide complementary prognostic value in survival prediction, offering clinicians a comprehensive basis for clinical decision-making.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of LNR- and LODDS-based predictive models for prognosis in non-elderly patients with locally advanced rectal cancer undergoing neoadjuvant therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月12日

查看全文
  • Wei Tao,
  • Yuxi Cheng,
  • Peng Wang,
  • Hong Wen,
  • Weidong Xiao

摘要

Purpose

The purpose of this study was to comprehensively assess the efficacy of lymph node ratio (LNR) and log odds of positive lymph nodes (LODDS) in predicting survival outcomes in non-elderly locally advanced rectal cancer (LARC) patients treated with neoadjuvant chemoradiotherapy (NCRT).

Methods

The 1643 non-elderly LARC patients undergoing NCRT between 2010 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database and were randomly assigned at a ratio of 7:3. We used Cox regression models to identify independent prognostic factors, then constructed nomogram models to predict cancer-specific survival (CSS) and overall survival (OS). The relative weight in nomogram models, receiver operating characteristic (ROC), area under the curve (AUC), concordance index (C-index), calibration curve, and decision curve analysis (DCA) were performed to evaluate and compare the predictive performance between LNR and LODDS.

Results

The distribution of LNR and LODDS showed that LODDS exhibited a more detailed stratification when LNR was equal to the extreme value. In predicting CSS, the LNR (hazard ratio (HR), 1.987; 95% confidence interval (CI), 1.375–2.872) and LODDS (HR, 1.568; 95% CI, 1.154–2.131) were independent risk factors in corresponding nomogram models. Regarding OS, the LODDS (HR, 1.387; 95% CI, 1.060–1.816) showed an independent predictive value. All evaluation methods confirmed the reliability of both models. Although the LNR-based model showed better performance for short-term CSS and the LODDS-based model demonstrated slightly better prediction for long-term CSS and OS, these two models showed largely comparable predictive ability.

Conclusions

The LNR and LODDS can provide complementary prognostic value in survival prediction, offering clinicians a comprehensive basis for clinical decision-making.